Enrico Zodio, CEO, procos
Can you describe better PROCOS’ new investments? In a continuous evolving world, PROCOS focused
Can you describe better PROCOS’ new investments? In a continuous evolving world, PROCOS focused
IBSA is a regular presence at the Cphi events. After Tokyo, you will be
Addressing some of the challenges in a transition to the circular bioeconomy, this paper first explores the use of next generation processing approaches to help move pharmaceutical, chemical, and biomaterial products from fossil carbon to its biobased alternative. It posits the use of system-oriented cluster technologies through the application of cluster governance to increase both collaboration and knowledge exchange and to help facilitate the transition to a circular bioeconomy in a fast and effective manner.
The concept of multi-catalysis is an emerging field targeting the development of new efficient catalytic systems combining multi-step synthesis in new ‘one-pot’ transformations or in multi-catalytic sequences. In this article, we will review the main classification of multi-catalysis strategies and illustrating some case-studies which combine different catalysis fields leading to some remarkable opportunities to outcompete classical approaches. Despite major challenges that need to be addressed with respect to compatibility issues and catalyst reactivity ordering, the implementation of such processes enables to strengthen the collaboration across many disciplines enhancing interdisciplinary competences.
Advancements in enzyme discovery and protein engineering have accelerated development of green, efficient synthetic routes to complex molecules and broadened implementation of biocatalysis for scalable manufacture of pharmaceutical intermediates. (S)-3-isobutyl-γ-aminobutyric acid (S-Pregabalin API), is a generic drug for the treatment of epilepsy and neuralgia. It has been previously synthesized via kinetic resolution and re-racemization under harsh conditions, which is inefficient and not eco-friendly. Herein, we describe the development of an enantioselective desymmetrization of 3-isobutylglutarimid utilizing an evolved D-hydantoinase to produce the Pregabalin Intermediate (IM) (R)-3-isobutyl glutaric acid monoamide en route to S-Pregabalin. Three rounds of computer-guided directed evolution were implemented towards improved activity, enantioselectivity and reduced substrate/product inhibition, providing a final variant that enables the full conversion of 240 g/L substrate into Pregabalin IM with excellent enantiomeric excess (ee) of >99.5%. The promising results demonstrated an economical and sustainable synthesis of S-Pregabalin starting from a prochiral substrate using an evolved D-hydantoinase.
Olefin metathesis is a powerful tool that enables unique bond disconnection strategies via carbon-carbon bonds. It has been employed in commercial scale synthesis across multiple industries and in multiple reaction types including ring-closing, cross, and ring-opening metathesis. Among these, macrocyclization by ring-closing metathesis stands out as a hallmark of the technology. However, ring-closing metathesis can also serve as a highly efficient entry to smaller rings. In this article, we highlight retrosynthetic strategies toward 5- and 6-membered nitrogen heterocycles, including in the context of a commercial drug manufacturing process.
As known, essential use, was initially proposed by scientists and later referred to in
Pharmaceutical innovation requires efficient production of active pharmaceutical ingredients (APIs) and the synthesis often involves one or more catalytic steps. Optimizing the catalyst and reaction conditions will result in improved product purity, yield, and safety and such optimization is often accompanied by significant cost reduction. Many companies do not have such capabilities for catalyst screening and optimization studies in-house, due to a lack of continuous need or limited resources to maintain a high-tech laboratory with high throughput testing equipment. In such case, a (pharmaceutical) company has to rely on Contract Research Organizations (CROs) for their catalyst research. Selecting an expert CRO involves assessing their effective communication, scientific knowledge, high throughput infrastructure, unbiased services, flexibility, and quality control. Addressing potential challenges with clear communication, prompt issue resolution, aligned goals, and adaptability is critical. Collaborating with an experienced CRO can accelerate market entry, reduce production costs, and drive competitiveness in the rapidly evolving pharmaceutical industry.
As the pharmaceutical industry undergoes transformations driven by innovation, outsourcing plays a vital role in drug development. Contract development and manufacturing organizations (CDMOs) are no longer simply production capacity providers but have become integral collaborative partners. Choosing the right CDMO is crucial amid global trends and events. At Veranova, we work closely with our partners to manage industry demands with confidence. In this article, Ken Zrebiec, Veranova’s Senior VP of Manufacturing Operations, explores how pharma companies leverage specialized CDMO expertise to enhance development capabilities.
Pharmaceutical companies recognize that the absence of standardized data can hinder their agility and innovation. This is particularly applicable to in-flight data, as it travels between different software solutions. Max Kelleher, Chief Operating Officer at Generis and Remco Munnik, a Director at Iperion, a Deloitte business, offer practical guidance on mapping and managing operational data to enhance business operations.